SA001 Mid dose ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
53シェーグレン症候群1

53. シェーグレン症候群


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05269810
(ClinicalTrials.gov)
May 29, 202024/2/2022Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's SyndromeMulticenter Double-blinded Randomized Phase 2a Clinical Trial to Evaluate the Efficacy of SA001 for Dry Eye and Mouth Dryness in the Patients With Primary Sjögren's SyndromePrimary Sjögren's Syndrome (pSS)Drug: SA001 Low dose;Drug: SA001 Mid dose;Drug: SA001 High dose;Drug: PlaceboSamjin Pharmaceutical Co., Ltd.NULLCompleted19 Years80 YearsAll28Phase 2Korea, Republic of